AGO2 Protein

Overview

AGO2 (Argonaute RISC Component 2) is the central effector protein of the RNA-induced silencing complex (RISC), mediating microRNA (miRNA) and small interfering RNA (siRNA)-guided gene silencing. It is the only Argonaute with catalytic slicer activity in humans, enabling it to cleave target RNAs, making it essential for both miRNA-mediated repression and siRNA-mediated RNA interference.^[1]

Structure

AGO2 contains multiple conserved domains that orchestrate small RNA binding and target cleavage:

N-Terminal Domain

• Lobes N-terminal: Flexible region involved in small RNA loading

• Contains the slicer-independent silencing functions

PAZ Domain (PIWI-Argonaute-Zwille)

• Binds the 3’ end of small RNAs (miRNAs, siRNAs)

• Recognizes the 2-nucleotide 3’ overhang of duplex siRNAs

• Anchors the guide strand while the passenger strand is discarded

Mid Domain

• Binds the 5’ phosphate of the guide small RNA

• Contains the seed region (nucleotides 2-8) that mediates target recognition

• Interfaces with GW182 for miRNA-mediated silencing

PIWI Domain

• Contains the catalytic DEDH Asp triad (D597, D669, D709)

• Possesses endonucleolytic slicer activity

• Binds the guide-target RNA duplex central region

Linker Regions

• Connect domains for conformational flexibility

• Allosteric regulation of catalytic activity

Normal Function

MicroRNA-Mediated Gene Silencing

AGO2 is the core component of miRNA-induced silencing:^[2]

miRNA Loading

1. Pre-miRNA processed by Dicer to ~22 nt miRNA duplex

2. miRNA duplex loaded onto AGO2

3. Passenger strand ejected; mature miRNA-AGO2 complex formed

Target Recognition

• miRNA “seed region” (nucleotides 2-8) pairs with complementary sites in target mRNA 3’ UTRs

• Additional pairing downstream supports stable binding

• Multiple miRNA binding sites cooperatively enhance repression

Silencing Mechanisms

• Transcriptional: Rarely, miRNA-AGO2 complexes enter nucleus to modulate transcription

• Post-transcriptional:

  • Translation inhibition (initiation and elongation blocks)

  • mRNA destabilization (deadenylation and decay)

  • Ribosome drop-off

Slicer-Dependent Functions

AGO2’s catalytic activity enables:

• siRNA-mediated cleavage: Complete complementarity leads to target mRNA cleavage

• miRNA “slicing”: In rare cases of near-perfect complementarity

• miRNA maturation: Some pri-miRNA processing by nuclear AGO2

Non-Catalytic Functions

AGO2 also mediates:

• miRNA-independent gene regulation

• Cellular stress responses

• Telomere maintenance

Role in Disease

Neurodegeneration

Alzheimer’s Disease

AGO2 dysfunction contributes to AD pathogenesis through multiple mechanisms:^[3]

• Altered miRNA processing: Global miRNA dysregulation in AD brains

• Amyloid processing: AGO2 regulates APP and BACE1 expression via miRNAs

• Tau pathology: miRNA-AGO2 targeting of tau kinases and phosphatases

• Synaptic dysfunction: miRNA-AGO2 dysregulation affects synaptic proteins

• Neuronal vulnerability: Reduced AGO2 activity in AD neurons

Parkinson’s Disease

• Alpha-synuclein aggregation affects miRNA processing^[4]

• AGO2 involved in regulating LRRK2 expression

• miRNA dysregulation in PD substantia nigra

Amyotrophic Lateral Sclerosis (ALS)

• AGO2 mutations cause familial ALS^[5]

• Altered miRNA processing in motor neurons

• Stress granule dynamics affected

Huntington’s Disease

• Mutant HTT sequesters AGO2

• Global miRNA dysregulation

• Derepression of beneficial miRNA targets

Cancer

AGO2 is frequently overexpressed in cancers:

• Promotes tumor growth and metastasis

• Therapeutic target under investigation

• Regulates oncogenes and tumor suppressors via miRNAs

Neurological Development

• Essential for neuronal development

• Regulates neurogenesis

• Controls axon guidance

• Modulates synaptic plasticity

Therapeutic Implications

Neurodegeneration

miRNA-Based Therapies

• miRNA mimics: Restore beneficial miRNA levels

• miRNA antagonists (antagomirs): Block pathogenic miRNAs

• AGO2 modulators: Enhance or inhibit function

siRNA Therapeutics

• AGO2 enables siRNA-based gene silencing

• Being developed for neurodegenerative targets

• Delivery to brain remains challenge

Cancer Therapy

• AGO2 inhibitors: Being developed to block oncogenic miRNA function

• Combination with chemotherapy: Sensitize tumors

• siRNA delivery: Exploit AGO2’s slicer activity

Key Publications

1. Meister et al., Mol Cell (2004): Identification of AGO2 as slicer

2. Yuan et al., Nat Struct Mol Biol (2005): Crystal structure of AGO2 PAZ domain

3. Nelson et al., Nat Rev Neurol (2017): miRNA dysregulation in AD

4. Wakimoto et al., J Neurosci (2019): AGO2 in PD and alpha-synuclein

5. Rybak-Wolf et al., Nat Rev Neurosci (2015): Non-canonical functions of AGO2

External Links

• Wikipedia

• NCBI Resources